

Optimal time to return to normality: parallel use of COVID-19 vaccines and circuit breakers

Michael B. Bonsall^{1*}, Chris Huntingford², Thomas Rawson¹

¹Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford, OX1 3PS, UK. ²UK Centre for Ecology and Hydrology, Wallingford, OX10 8BB, UK.

*Corresponding author: michael.bonsall@zoo.ox.ac.uk

Word count: 5373

Tables: 2

Figures: 6

1 Abstract

2 By January 2020, the COVID-19 illness has caused over two million deaths. Countries have re-
3 stricted disease spread through non-pharmaceutical interventions (e.g., social distancing). More
4 severe “lockdowns” have also been required. Although lockdowns keep people safer from the virus,
5 they substantially disrupt economies and individual well-being. Fortunately, vaccines are becom-
6 ing available. Yet, vaccination programs may take several months to implement, requiring further
7 time for individuals to develop immunity following inoculation. To prevent health services being
8 overwhelmed it may be necessary to implement further lockdowns in conjunction with vaccination.
9 Here, we investigate optimal approaches for vaccination under varying lockdown lengths and/or
10 severities to prevent COVID-19-related deaths exceeding critical thresholds. We find increases in
11 vaccination rate cause a disproportionately larger decrease in lockdowns: with vaccination, se-
12 vere lockdowns can reduce infections by up to 89%. Notably, we include demographics, modelling
13 three groups: vulnerable, front-line workers, and non-vulnerable. We investigate the sequence of
14 vaccination. One counter-intuitive finding is that even though the vulnerable group is high risk,
15 demographically, this is a small group (per person, vaccination occurs more slowly) so vaccinating
16 this group first achieves limited gains in overall disease control. Better disease control occurs by
17 vaccinating the non-vulnerable group with longer and/or more severe lockdowns.

18

19 **Keywords:** COVID-19, optimal control, vaccination, social distancing, mathematical mod-
20 elling, population cohorts

21 Introduction

22 The emergence of the SARS-CoV-2 virus in late 2019 has had, subsequently, devastating conse-
23 quences across the globe, with all countries reporting levels of virus infection affecting public health
24 responses. Since the emergence of this novel coronavirus, the policies implemented (in part using
25 insights from previous pandemics) have focused on non-pharmaceutical interventions (NPIs) and
26 approaches such as travel bans, limited household mixing, stay-at-home orders ('lockdowns') and
27 quarantines, social distancing and the closure and restriction of large mass gatherings. These NPIs
28 require effective implementation, behavioural shifts and continued political and public support [1, 2]
29 and have mitigated disease spread, levels of infection, rates of morbidity, and mortality [3, 4, 5].
30 While these measures have suppressed related COVID-19 deaths, NPIs have macroscale impacts
31 on the economics of many nations [6, 7, 8], as well as, arguably, microscale implications, affecting
32 the mental well-being of many individuals [9].

33
34 Although these non-pharmaceutical approaches have some success in reducing virus spread, they
35 are not a sustainable strategy, and other treatment-based approaches are required [10]. Several
36 candidate vaccines are in Phase III trials reporting efficacies from 70% to more than 90% [11]. At
37 the end of 2020, two vaccines (Pfizer-BioNTech and Oxford-AstraZeneca) have been approved by
38 regulators in some countries as safe for general use.

39
40 Even under the assumption that vaccines work as intended, the challenges now are three-fold. The
41 first is to instigate mass vaccination programs. The second is to prevent health services being
42 overwhelmed in the meantime, recognising that to vaccinate a nation takes time and that there is
43 a lag of some weeks after inoculation before high immunity levels are achieved. The third issue
44 is that many citizens are weary, and persuading them to follow restrictive rules while a vaccine
45 appears imminent may be difficult. That is, many in society could be overly confident that the
46 threat posed by the virus is reduced in light of the announcements of a successful vaccine, failing
47 to recognise there remains a time lag before full levels of herd immunity are realized.

48
49 There is therefore a requirement to determine the optimal balance between five factors. These fac-

tors are: (1) total number of deaths (that in some situations be regarded as a proxy for healthcare capacity), (2) vaccination rate, (3) the level of lockdown restrictions impacting virus transmission rates, (4) the order in which different population groups are inoculated and (5) time spent in lockdown.

54

Here we solve aspects of this optimisation problem, based on predictions from a standard SIR (Susceptible, Infected and Recovered) model, modulated by a vaccination program. Specifically, we calculate for prescribed total number of deaths, achievable vaccination rates of different groups and transmission rates, the optimal policy of vaccination delivery amongst population groups so as to minimise time spent in lockdown. We introduce heterogeneity in terms of group structure, with a focus on three main population groups of vulnerable, front-line worker, and non-vulnerable. Our overarching aim is to demonstrate how vaccination and lockdowns can, and should, be used together to achieve optimal disease control. In the the next section we introduce the mathematical frameworks and methods of analysis. In the results, using numerical approaches and as parameterised for the UK epidemic, we illustrate how different levels of vaccination, lockdown severity and prescribed maximum level of disease determine a minimal lockdown length for a derived optimal strategy of vaccination across our three groups. In the discussion, we present our results in light of previous work on vaccination and non-pharmaceutical interventions.

68 Mathematical Models

69 Basic Unstructured Model

Mathematical models such as the SIR (Susceptible, Infected, Recovered) models are commonly used frameworks to describe disease transmission [12]. To explore the combined effects of vaccination and lockdowns on controlling infections, we begin by using a simple extension to an SIR framework in which vaccinated individuals (V) are accounted for separately from recovered (R) individuals. The dynamics for susceptible (S) individuals is such that the rate of change of the number of susceptibles decreases due to individuals becoming infected, is increased by any loss of immunity of people who have previously recovered, lowered by background death rate and lowered as people

77 are vaccinated. Hence, this gives for the time evolution of S :

$$\frac{dS}{dt} = -\frac{\beta S(t)I(t)}{N(t)} + \sigma R(t) - \mu S(t) - \nu S(t). \quad (1)$$

78 The dynamics for infected individuals are such that the number increases as susceptibles pass
79 through an incubation period of length τ become infectious. The number of infected decreases as
80 people either die from COVID-19, die naturally, or recover. Hence I follows:

$$\frac{dI}{dt} = \frac{\beta S(t-\tau)I(t-\tau)}{N(t-\tau)} \exp(-\mu\tau) - (\alpha + \mu + \gamma) I(t). \quad (2)$$

81 The dynamics for recovered individuals are such that the number increases as people recover from
82 infection, or decreases due to vaccination, non-COVID-19-related death, or loss of immunity, giving:

$$\frac{dR}{dt} = \gamma I(t) - (\nu + \mu + \sigma) R(t). \quad (3)$$

83 Finally the dynamics for the total number of vaccinated individuals is dependent on the vaccination
84 rate, lowered only by a background death rate, and therefore there is an assumption of no immunity
85 loss for those inoculated and no onward transmission of virus once individuals are vaccinated.
86 Hence:

$$\frac{dV}{dt} = \nu(R(t) + S(t)) - \mu V(t). \quad (4)$$

87 In equations (1)-(4), parameter β is the disease transmission rate, σ the loss of immunity, μ is the
88 background death rate, ν is the vaccination rate (acting on both susceptible and recovered individ-
89 uals), τ is the incubation window (and $\exp(-\mu\tau)$ is the survival rate through the incubation
90 window), α is the disease induced death rate, and γ is the disease recovery rate. We introduce
91 circuit breakers as a reduction in transmission such that the value of β reduces to a range of values.
92 The total number of people is $N(t) = S(t) + I(t) + R(t) + V(t)$.

93

94 The optimal control problem (Appendix 1) is formulated as finding an optimal vaccination rate
95 ($\nu(t)$) under different levels of lockdown restriction (i.e. different levels of β) within a time interval

96 $[0, T]$ so as to minimize ‘costs’ of vaccination and disease-induced deaths above a threshold Z :

$$\min_{0 < \nu \leq 1} (J[\mathbf{x}, \nu]) = \min_{0 < \nu \leq 1} \left(\int_0^T \left[\frac{\nu^2(t)}{2} V(t) + \exp(\alpha I(t) - Z) \rho \right] dt \right) \quad (5)$$

97 with control inequality constraint $0 \leq \nu \leq 1$, subject to the system of governing differential equa-
98 tions ($\mathbf{x} = [S, I, R, V]^T$) and initial conditions $\mathbf{x}(t(0)) = \mathbf{x}_0$, where T is the length of epidemic (and
99 not the lockdown period) and ρ is a scaling constant. The increasing quadratic ‘costs’ associated
100 with vaccination assumes that vaccination becomes increasingly difficult as the number of daily
101 vaccinated individuals increases - this is one way to describe ‘vaccination demand’ (see below for
102 other approaches to this on the disease dynamics). The function $\exp(\alpha I(t) - Z)$ describes the
103 difference between the number of disease-induced deaths at time point t and a considered threshold
104 value Z . Raising this difference to an exponent ensures that the contribution of $(\alpha I - Z)$ is small
105 if $\alpha I < Z$ and that $(\alpha I - Z)$ contributes greatly to the cost functional J (equation (5)) when
106 $\alpha I > Z$. This means that deaths, above a threshold Z , are increasingly penalised, corresponding
107 to exceeding a normal acceptable level of healthcare capacity. Here, ρ is a scaling constant that,
108 within the objective functional, weights the relative contribution of the threshold mortality effects
109 compared to vaccination ‘costs’ on the minimisation.

110 Structured Model

111 We extend the model to incorporate demographic structure, corresponding to different groups of
112 people. Individuals are classed as ‘front-line workers’ (FR), ‘vulnerable’ (V) individuals or ‘non-
113 vulnerable’ (NV) individuals. Transmission could occur differently within and between groups,
114 and we define $\beta_{j,i}$ as the probability that an infected individual in group i infects a susceptible
115 individual in group j . The force of infection (the *per capita* rate of infection) for the i^{th} group is
116 then:

$$\lambda_j = \sum_i \beta_{j,i} \frac{I_i}{N_i}, \quad (6)$$

117 where $\frac{I_i}{N_i}$ is the frequency-dependent transmission function in the i^{th} group. The expected probabil-
118 ity that a susceptible individual (in group j) acquires an infection, from any source, is then the sum

119 of the products of transmission rate and proportion of infected individuals in the i^{th} group, for all i .

120

121 The use of equation (6) allows us to retain the mathematical structure of the epidemiological

122 dynamics of (1)-(4), now applied to the i^{th} group as:

$$\frac{dS_i}{dt} = -\lambda_i S_i(t) + \sigma R_i(t) - \mu S_i(t) - \nu_i S_i(t), \quad (7)$$

$$\frac{dI_i}{dt} = \lambda_i(t - \tau) S_i(t - \tau) \exp(-\mu\tau) - (\alpha_i + \mu + \gamma_i) I_i(t), \quad (8)$$

$$\frac{dR_i}{dt} = \gamma_i I_i(t) - R_i(t) (\nu_i + \mu + \sigma), \quad (9)$$

$$\frac{dV_i}{dt} = \nu_i (R_i(t) + S_i(t)) - \mu V_i(t), \quad (10)$$

123 where vaccination rate (ν_i), disease-induced death rate (α_i) and recovery rate (γ_i) are group-specific

124 parameters. The rate of loss of immunity (σ), background death rate (μ), and virus incubation time

125 (τ) are population-level parameters are instead independent of group structure. For each group

126 $N_i(t) = S_i(t) + I_i(t) + R_i(t) + V_i(t)$.

127

128 **Optimal vaccination**

129 To investigate the optimal vaccination level under different levels of lockdown severity to keep

130 disease-induced mortality below a critical threshold, we solve the optimal control problem defined

131 by equation (5) following Pontryagin's maximum principle [13]. This solution is for the unstructured

132 model (equations (1)-(4), considering the population as a single cohort defined by S , I , R and V

133 subgroups). Using the objective functional (equation (5)), adjoint equations, and control inequality

134 constraint [14], optimal dynamic vaccination rates ($\nu(t)$) are calculated for varying levels of reduced

135 disease transmission (β). We use a modified Runge-Kutta method (a forward-backward-sweep

136 algorithm [13]) to find the optimal outcome. The full details of the corresponding Hamiltonian and

137 adjoint equations used to identify the optimum vaccination rate are presented in the Appendix.

138 **Vaccination, different cohorts and lockdowns**

139 We also investigate the interplay between vaccination strategies amongst population groups and
140 length of lockdowns, so as to achieve the optimal suppression of the virus (in terms of disease-
141 induced mortality) for a variety of considered lockdown lengths and effectiveness, while keeping
142 cumulative mortalities below a critical threshold. To do so we use the structured model (equa-
143 tions (7)-(10)). This model framework accounts for the three groups of front-line workers (FR),
144 vulnerable (V) and non-vulnerable (NV), and was solved numerically over 150 days. The model
145 was parameterized with parameters estimated to be appropriate to the UK (Tables 1 & 2). We
146 calculate the optimum vaccination strategies across different population groups.

147 **Optimal lockdown times**

148 Importantly, we investigate the hypothesis that lockdowns can be used to support, in parallel, on-
149 going vaccination programs in order to prevent infection rates crossing key thresholds. In particu-
150 lar, we consider how different strategies concerning the order in which groups vulnerable, front-line
151 workers, and non-vulnerable are inoculated, for the same maximum infection rate thresholds, im-
152 pacts on length of lockdown. Hence the optimum we search for is the shortest lockdown strategies
153 for each threshold. Again, we solve the structured epidemiology model (equations (7)-(10)) numer-
154 ically for different sequences of vaccination over 150 days. The chosen sequence is to deliver vaccine
155 to first group for 30 days, first and second group from 31-60 days and all groups after 60 days.
156 Critically, the vaccination rates, expressed as fraction of cohort vaccinated per day, are common to
157 each group. This implies that as the vulnerable group is smaller, the number of people vaccinated
158 per day is smaller, likely reflecting the actual situation. The optimal outcome in terms of group
159 order vaccination strategy to achieve the shortest lockdown times, while maintaining cumulative
160 mortalities below a critical threshold, is also determined for varying lockdown severities (i.e. levels
161 of transmission reduction).

162 **Vaccination demand: declining vaccine uptake rates**

163 A further component that we consider is vaccination elasticity. This process is used to describe how
164 supply and demand varies given changes in (usually) price of a commodity [15]. In epidemiology,

165 this idea of elasticity in demand has been linked to vaccine uptake and disease prevalence [16]. With
166 inelastic demand in vaccine, as disease prevalence falls and assuming that vaccination levels can be
167 maintained, then the public health benefits of vaccination (and the resulting herd immunity) can
168 be maintained as infection levels fall. However if vaccine uptake is elastic with respect to disease
169 prevalence, such that as disease prevalence falls individuals are less likely to take a vaccine, then
170 the public health control of infections can be more challenging. Elasticity can prevent achieving
171 the vaccination levels needed to reach the critical threshold for herd immunity.

172

173 Here we investigate the role of vaccine elasticity demand, via a time evolving function $\nu(t)$, on
174 disease outcomes (in terms of cumulative levels of mortality) under different lockdown lengths and
175 severities. Our working hypothesis, that we test, is that lockdowns can be used to offset vaccine
176 elasticities to maintain and/or achieve virus control. We use numerical approaches to solve the full
177 structured model over time (150 days) to find the optimal vaccination level, lockdown duration and
178 severities that keep cumulative mortality below a critical threshold.

179

180 The code used for all numerical analyses and simulations is available at <https://osf.io/xvunt/>.

181 Results

182 Optimal vaccination

183 Solving the constrained optimisation problem (Appendix) shows that the optimal vaccination strat-
184 egy is a function of the ratio between the susceptibles, recovered and vaccinated individuals:

$$\nu^* = \frac{\lambda_1 S + \lambda_3 R - \lambda_4 (R + S)}{V}$$

185 where λ_i are adjoint (Lagrange) multiplier variables associated with the state variables (S , R and
186 V). While the state variables constrain the minimisation of the objective functional (5), these multi-
187 pliers can be thought of as representing costs of violating the state variable constraints (Appendix).

188

189 Solutions for the optimal vaccination rate are shown in Figure 1. As planned, coupled with the

190 threshold mortality condition, an optimal vaccination strategy can suppress the COVID-19 epi-
191 demic (Figure 1A). However, for increasing lockdown severity (20-80% reduction in transmission
192 i.e. β), this can lead to the infection fading out without the characteristic epidemic growth curve
193 associated with general S-I-R type dynamics.

194

195 With a canonical parameter set (Figure 1), optimal vaccination strategies that keep daily disease-
196 induced mortality below a critical threshold ($Z = 100$) and can reduce peak numbers of infections
197 by $\sim 74\%$ (with just vaccination) through to $\sim 89\%$ (with vaccination coupled with a 80% reduc-
198 tion in transmission rate), all compared to the no-control scenario.

199

200 The (optimal) vaccination strategy is influenced by the stringency of the mortality threshold (Z)
201 (Figure 1B). As might be expected, a more stringent threshold necessitates higher levels of vaccina-
202 tion to achieve the expected level of control to ensure disease-induced mortality remains below that
203 critical threshold. As also expected, decreasing potential disease transmission (e.g. through the
204 use of NPIs) offsets the need for high levels of vaccination to achieve the necessary levels of disease
205 control (Figure 1B). Notable is the strong non-linearity in Figure 1; where, as a result of reductions
206 in transmission (i.e. effects of different lockdown scenarios), for different critical thresholds the
207 optimal vaccination rate declines in different ways for different critical thresholds.

208 **Vaccination, different cohorts and lockdowns**

209 Under the structured epidemiological dynamics (equations 7-10), cumulative levels of disease-
210 induced mortality is influenced by the length of time in, and severity of, lockdown along with the
211 vaccination rate (Figure 2). Increasing the vaccination rate decreases the need for longer lockdowns
212 and, under high vaccine coverage, the necessity for these lockdowns. While still essential, lockdowns
213 can instead be of short duration when partnered with a vaccination program. This is again to limit
214 cumulative mortalities to different levels. Under lockdowns where the level of transmission is only
215 reduced by 20% or 40%, cumulative mortalities due to the virus are expected to be excessively high
216 unless vaccine coverage is also high. Under more severe lockdowns where transmission is reduced by
217 60% or 80% (Figure 2), shorter circuit breakers can be sufficient to limit disease-induced mortalities.

218

219 More specifically, for vaccination to be effective in reducing cumulative mortality (set here at
220 $\sim 50,000$ over 150 days), and in the range of anticipated vaccination rate (0.006 - 0.0152), then
221 lockdown severity needs to reduce transmission by at least 60% or lockdowns need to be unac-
222 ceptably long and extend for more than 90 days. Furthermore, these sort of lockdowns or circuit
223 breakers can be used to offset weakly efficacious vaccine rates to ensure that disease-related mor-
224 talities are kept in check below the (nominal) threshold of 50,000 (Figure 3).

225

226 To understand more fully vaccine delivery strategies between different parts of society, we begin by
227 determining how focusing initial vaccine delivery on single groups affects the likelihood of keeping
228 levels of mortality below the (optimal) threshold. If vaccines are delivered singly to vulnerable or
229 key worker groups then lockdowns would still be necessary and they would need to be reasonably
230 severe ($> 60\%$ reduction in transmission) to reduce cumulative mortality below key thresholds
231 (Figure 4). Notable is that less severe lockdowns when vaccinating either of these two groups are
232 not sufficient to keep cumulative mortality below a critical threshold. This key finding is critical, and
233 requires consideration in light of the decision by many countries to vaccinate the most vulnerable
234 first. The reason for this finding is due to the demographic differences between these two groups
235 (where population sizes in these groups are relatively small) compared to the non-vulnerable group
236 (which contains the majority of the population). For example, consider a vulnerable (V) group of
237 500,000 people, and a non-vulnerable (NV) group of 10,000,000 people. If we vaccinate roughly 5%
238 of each group each day this would lead to vaccinating either 25,000 vulnerable people, or 500,000
239 non-vulnerable people, daily. Hence, even if the vulnerable people are an order of magnitude more
240 likely to die of COVID-19, more lives will be saved by vaccinating the 500,000 non-vulnerable group.
241 For some nations this scenario might be likely, if non-vulnerable people can be vaccinated (in units
242 of people per day) at a speed that is an order of magnitude larger - for instance through mass
243 vaccination centres that the vulnerable are unable to reach. In those circumstances, a more robust
244 approach to achieve keeping mortality below the critical threshold would be to vaccinate across the
245 non-vulnerable group and gain from the related shorter and/or less severe lockdown (Figure 4).

246 Optimal lockdown times

247 Optimal outcomes, in terms of shortest possible lockdown times based on order of vaccination be-
248 tween cohorts, are shown in Figure 4 for different transmission reductions. This summary figure
249 shows how different combinations of vaccination and lockdown interventions can lead to successful
250 disease control (in terms of minimizing cumulative mortalities) (Figure 4). With low vaccination
251 rate (e.g. $\nu = 0.005$), and depending on the severity of lockdown, lockdown durations could be
252 as short as 20 days (for a 80% reduction in β). Alternatively, a lockdown may be 30 days (for
253 60% reduction in β) or 50 days (for 40% reduction in β) for successful virus control. However,
254 under this level of vaccination ($\nu = 0.005$), it is simply not feasible for a lockdown where β is only
255 reduced by 20% to keep cumulative mortality below the (nominal) 80,000 threshold.

256
257 We illustrate how vaccinating different groups in different sequences can influence strategies to
258 achieve the optimal outcome, and most notably impact the time required in lockdown. If a strat-
259 egy is adopted to vaccinate different groups over sequential 30 day periods (and continuing this
260 vaccination strategy once initiated for each group), then the choice of longitudinal sequences in-
261 fluences the choice of lockdown duration and/or severity to achieve optimal disease control. For
262 the majority of sequences, moderate to severe lockdowns are needed to achieve the optimal goal of
263 keeping cumulative mortality below a critical threshold (Figure 5). However, adopting a strategy
264 in which the non-vulnerable group is vaccinated first, followed by the front line worker group fol-
265 lowed by the vulnerable group (“NV-FR-V”; Figure 5) allows lockdowns of weaker severity (where
266 disease transmission is reduced by only 20%), albeit these might be of longer duration, to be used
267 to achieve the optimal goal. Apart from this sequence of vaccine delivery, there is again no feasible
268 vaccination strategy where weak lockdowns (transmission is reduced by 20%) would allow mortality
269 levels to be kept below 50,000 people. Targeting the non-vulnerable group in the first or second
270 wave of vaccination allows a broad set of lockdown severity (40%-80% reduction in transmission)
271 strategies to be implemented. If a strategy is adopted to target vulnerable and front line workers
272 then it will require moderate to severe lockdowns (60%-80% reductions in transmission) to achieve
273 the optimal outcome for disease control (Figure 5).

274 **Vaccination demand: declining vaccine uptake rates**

275 Vaccine demand and uptake can influence the outcome of disease mitigation and control measures.
276 One concern is that as a substantial number of people are vaccinated, and potentially in tandem
277 with initial declines in infection rates, then there will be an emerging complacency and vaccine
278 adoption will fall. However, exponentially declining vaccine uptake is most likely to disrupt control
279 measures and lead to resurgences in disease spread and increases in mortalities (Figure 6). Again,
280 the use of lockdowns of different durations and/or severities can mitigate against this sort of loss of
281 control. Even for weakly restrictive lockdowns (where disease transmission is only reduced by 20%)
282 and vaccine uptake declines exponentially (here set at 2.0×10^{-4} per day), long duration lockdowns
283 can reduce cumulative mortality levels (Figure 6). In fact, more severe lockdowns for this sort
284 of loss of vaccine uptake can limit the duration of these lockdowns and lead to effective disease
285 control.

286 **Discussion**

287 Here, using mathematical modelling approaches we have investigated how combining vaccinations
288 and lockdowns can be used to control virus levels (in terms of disease induced levels of mortality).
289 We show that for different levels of vaccination (or vaccine efficacy), lockdowns of different dura-
290 tion and/or severity can be implemented to mitigate levels of mortality. In particular, we highlight
291 particular combinations of vaccination and lockdowns that can achieve effective virus control. Out
292 of a number of potential exit strategies that include promoting natural herd immunity, virus elim-
293 ination or releasing lockdowns as treatments become available, Sheikh et al. (2020) [17] advocate
294 approaches whereby lockdowns are relaxed and virus infection levels are managed through tracing
295 strategies. While this might be an achievable endgame, to reach this point requires, as we have
296 demonstrated here, requires combinations of approaches. Rather than relaxing lockdowns as a
297 strategy, our analysis suggests that combining them with low coverage vaccination (or low vaccine
298 efficacy) allows optimal solutions to be found to mitigating levels of disease.

299

300 A non-random distribution of vaccinations may be ineffective even in behaviourally homogeneous

301 populations [18]. Moreover, for heterogeneous populations, evaluating the full contact matrix to
302 derive an appropriate vaccination strategy may be impossible. Here, as we use the simplifying ap-
303 proximation that within and between contacts are similar ($\beta_{ji} = \beta$), the non-random distribution
304 of vaccines can be inefficient at achieving sufficient coverage for the disease to fade out. Similar
305 findings for age-structured models [19] and vaccine sharing strategies (Huntingford et al. in re-
306 view) corroborate this finding. Here, this occurs due to population size differences between the
307 groups and the relative differences that this has on mitigating levels of disease-induced mortality.
308 In particular, we find that vaccinating individuals in the vulnerable group (a relatively small group)
309 must be rolled out together with mass vaccination across the wider larger non-vulnerable group to
310 achieve necessary public health benefits of reducing mortality and herd immunity.

311

312 These sorts of well-planned vaccination strategies may to lead to spatial and temporal clusterings.
313 These groupings and others such as social clusterings generate further levels of heterogeneity that
314 achieving optimal outcomes based on vaccination strategies alone may be challenging. Groups that
315 eschew vaccinations may make disease control more difficult. In fact, ‘clustering of exemptions’ ne-
316 cessitates greater vigilance around the emergence of a ‘critical mass’ where individual decisions to
317 decline vaccination impinge on the collective (public health) benefit and restricts vaccine coverage
318 [20, 21, 22]. Here, we account for these factors, and consider declining vaccination uptake should
319 groups decide to alter behaviours during mass-roll out of the vaccine. As expected, rapid (expo-
320 nential) decline of vaccine uptake is most precipitous in terms of optimal disease control outcomes.
321 Our results confirm that lockdowns and other non-pharmaceutical interventions can be used to
322 mitigate against the effects of social clusterings and loss of vaccine uptake/efficiencies. However,
323 rapidly understanding the way in which these groupings form will be critical to determine how
324 robust in terms of severity and duration lockdowns need to be to achieve optimal disease control
325 outcomes for COVID-19.

326

327 Optimal control approaches have been widely used in understanding the control of infectious dis-
328 eases and there have been several applications to understanding the SARS-CoV-2 pandemic. For
329 instance, our own work [23, 24](Huntingford et al. in review) has focused on the use of optimal

330 control approaches to understand how the use of NPIs and lockdowns could be eased so as to mini-
331 mize hospitalizations, and how circuit-breakers could be optimally used to disrupt epidemic peaks,
332 and the optimal approaches to sharing vaccines between nations. Other studies have focussed on
333 the use of optimal control approaches for mitigating disease mortalities and the use of NPIs [25]
334 and how vaccinations could be administered to minimize mortalities [26].

335

336 Perkins & Espana (2020) [25] use COVID-19 epidemic data from the USA to parameterise an un-
337 structured SEIR framework with additional asymptomatic, hospitalisation and vaccinated classes
338 to investigate the optimal use of NPIs. In their formulation, only susceptible individuals received
339 the vaccine and optimal solutions then focused on minimizing both use of NPIs (as a reduction
340 in disease transmission) and deaths. Perkins & Espana (2020) find that relaxing NPIs too soon
341 can have major implications for longer term disease control and that maintaining stricter levels of
342 control, minimizes deaths. Here, our results support this finding that the severity of control (i.e.
343 as expressed as reductions in disease transmission β) can mitigate levels of disease-induced deaths.
344 Our main finding is that in addition, with vaccination, optimal strategies to minimize deaths can,
345 under certain conditions, offset the need for severe or long lasting NPIs.

346

347 Libotte et al. (2020) [26] use the SIR and optimal control approach to investigate vaccine delivery
348 strategies. In their study, the objective functional is focused to minimize the number of infected
349 individuals and the total amount of vaccine required. Their use of an inequality constraint is used
350 to model limitations related to vaccine availability and production. With the choice of linear terms
351 in the objective functional, the optimal solutions are on-off (bang-bang) control with variable time
352 between delivery of vaccines to minimize the number of infections. Our results contrast with this
353 bang-bang control. This highlights the effects of different uses of cost structures. Here, we use
354 quadratic increasing costs to capture difficulties in achieving vaccination target as the number of
355 vaccinated individuals increases, as well as the application of the optimal control problem to a
356 structured (rather than unstructured) population. In our key result, the sequence of vaccine de-
357 livery to different groups is critical to achieving disease control and minimizing the public health
358 burden of disease-induced deaths.

359

360 As noted, neither of these previous studies consider population structure and the interaction be-
361 tween vaccines and NPIs as concomitant approaches to disease control and minimizing disease
362 induced deaths. We argue that these sort of optimal control approaches provide a ‘weight of ev-
363 idence’ for more pluralistic approaches to controlling the infection, and especially as appropriate
364 constraints can be included in solving numerical optimal models of the epidemiological dynamics.

365

366 In conclusion, although vaccinations for COVID-19 are starting to be approved for use, and coun-
367 tries are thereby implementing mass inoculation programs, many places are experiencing further
368 waves of infection. This requires a difficult balance between providing the benefits of vaccination
369 programs as a route to returning to normality, yet still requiring the continued use of NPIs (such
370 as strict lockdown rules) in the interim. For this reason, it is timely to investigate the options
371 available to minimise the time in lockdown.

372

373 Here, we have used a mathematical model to investigate the combined effect of lockdowns and
374 during a mass vaccination plan. For the three quantities of different rates of vaccinations, extent
375 of restrictions that impacts virus transmission and number of deaths that will protect health ser-
376 vices, we derive the shortest lockdown length. Our mathematics of optimisation determines the
377 shortest lockdown time for the three parameters, and critically, across different options of which
378 groups of people to vaccinate first. We use three discrete cohorts of people, of vulnerable, front-
379 line workers and non-vulnerable. As an additional component to our numerical calculations, we
380 also allow for “vaccine elasticity”, where individuals may become less concerned about receiving
381 a vaccine as disease infection rates fall. We also allow consideration of vaccines that are not fully
382 efficacious as we evaluate optimal outcomes in terms of shortest lockdowns for prescribed maximum
383 levels of mortality. We argue that our use of appropriately developed structured epidemiological
384 models provide a robust way to investigate these epidemiological outcomes. Our optimal control
385 approaches allow the best combinations (here for parameter constraints applicable to the UK) to be
386 determined. However, these outcomes are parameter-dependent, and might change across different
387 locations and/or temporal scales.

388

389 Our headline findings are as follows. As might be expected, to require relatively short lockdowns,
390 NPIs have to be sufficiently severe as to suppress transmission. Less effective vaccines imply longer
391 lockdowns, as does a larger vaccine elasticity. However, to achieve appropriate levels of disease
392 control and contrary to the standard approach of vaccinating the most vulnerable first, we find
393 that the optimal vaccination policy is to inoculate the larger (non-vulnerable) demographic group
394 first, then followed by front-line workers and then the vulnerable. While this finding might ap-
395 pear counter-intuitive, given the order-of-magnitude difference in death rate for those encouraged
396 to shield against COVID-19 (i.e. in the vulnerable category). The reason for this finding is our
397 analysis assumes that the time required to vaccinate the vulnerable group is identical to that of the
398 much larger non-vulnerable group. As the non-vulnerable group is much larger, many more people
399 are vaccinated per day under that assumption, causing the disease to decline more quickly and yet
400 still constraining the overall number of deaths.

401

402 We hope our analysis will encourage additional theoretical and empirically validated studies to
403 understand further how the demographic heterogeneity (by group or age structure) impacts the
404 epidemiological dynamics and outcomes of virus spread. Such analyses can include the associated
405 immediate effects of lowered transmission by lockdowns, both within and between different groups,
406 as well as the impact of choice of vaccination order on required lockdown lengths and sterilising/non-
407 sterilising effects of vaccination in preventing onward disease transmission. In particular, the impact
408 of choice of vaccination order on required lockdown lengths is worthy of substantial on-going inves-
409 tigation.

410 **Tables**

Parameter	Definition	Value	Source(s)
β	transmission rate	0.016	[23]
μ	background mortality rate	2.273×10^{-5}	[27]
τ	incubation time	5.1	[28, 29]
ν	vaccine efficacy	0.001 – 0.05	this work
σ	loss of immunity	(set to 0)	this work

Table 1: Population-level parameters fixed across all groups.

Front-line worker group			
Parameter	Definition	Value	Source(s)
α	disease-induced death rate	0.0032	[30]
γ	recovery rate	~ 0.1	[31, 32]
Vulnerable individual group			
Parameter	Definition	Value	Source(s)
α	disease-induced death rate	0.064	[30]
γ	recovery rate	~ 0.06	[32, 33]
Non-Vulnerable individual group			
Parameter	Definition	Value	Source(s)
α	disease-induced death rate	0.0032	[30]
γ	recovery rate	~ 0.1	[31, 32]

Table 2: Population-level parameters specific to the different individual groups.

411 **References**

- 412 [1] Theodore Lytras and Sotirios Tsiodras. Lockdowns and the COVID-19 pandemic: What is
413 the endgame? *Scandinavian Journal of Public Health*, 1403494820961293, 2020.
- 414 [2] Dalia Dawoud. Emerging from the other end: Key measures for a successful COVID-19
415 lockdown exit strategy and the potential contribution of pharmacists. *Research in Social and*
416 *Administrative Pharmacy*, 17(1):1950–1953, 2021.
- 417 [3] Seth Flaxman, Swapnil Mishra, Axel Gandy, H Juliette T Unwin, Thomas A Mellan, Helen
418 Coupland, Charles Whittaker, Harrison Zhu, Tresnia Berah, Jeffrey W Eaton, et al. Es-
419 timating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*,
420 584(7820):257–261, 2020.
- 421 [4] Hien Lau, Veria Khosrawipour, Piotr Kocbach, Agata Mikolajczyk, Justyna Schubert, Jacek
422 Bania, and Tanja Khosrawipour. The positive impact of lockdown in Wuhan on containing
423 the COVID-19 outbreak in China. *Journal of Travel Medicine*, 27(3):taaa037, 2020.
- 424 [5] Ruth D Carlitz and Moraka N Makhura. Life under lockdown: Illustrating tradeoffs in South
425 Africa’s response to COVID-19. *World development*, 137:105168, 2020.
- 426 [6] André Sapir. Why has COVID-19 hit different European Union economies so differently?
427 *Bruegel Policy Contribution*, 18, 2020.
- 428 [7] OBR (Office for Budget Responsibility) (2020). Coronavirus analysis. [https://obr.uk/
429 coronavirus-analysis/](https://obr.uk/coronavirus-analysis/). Accessed: 2020-09-29.
- 430 [8] Matthieu Teachout and Céline Zipfel. May 2020 Policy Brief: The economic impact of COVID-
431 19 lockdowns in Sub-Saharan Africa. *International Growth Centre*, 2020.
- 432 [9] Emily A Holmes, Rory C O’Connor, V Hugh Perry, Irene Tracey, Simon Wessely, Louise
433 Arseneault, Clive Ballard, Helen Christensen, Roxane Cohen Silver, Ian Everall, et al. Multi-
434 disciplinary research priorities for the COVID-19 pandemic: a call for action for mental health
435 science. *The Lancet Psychiatry*, 7(6):547–560, 2020.

- 436 [10] Neil Ferguson, Daniel Laydon, Gemma Nedjati-Gilani, Natsuko Imai, Kylie Ainslie,
437 Marc Baguelin, Sangeeta Bhatia, Adhiratha Boonyasiri, Zulma Cucunubá, Gina Cuomo-
438 Dannenburg, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce
439 COVID19 mortality and healthcare demand. *Imperial College London*, 10:77482, 2020.
- 440 [11] Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti,
441 Parvinder K Aley, Brian Angus, Vicky L Baillie, Shaun L Barnabas, Qasim E Bhorat, et al.
442 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an
443 interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The*
444 *Lancet*, 397(10269):99–111, 2020.
- 445 [12] Roy M Anderson and Robert M May. *Infectious diseases of humans: dynamics and control*.
446 Oxford University Press, 1992.
- 447 [13] Suzanne Lenhart and John T Workman. *Optimal control applied to biological models*. CRC
448 press, 2007.
- 449 [14] Morton I Kamien and Nancy Lou Schwartz. *Dynamic optimization: the calculus of variations*
450 *and optimal control in economics and management*. Courier Corporation, 2012.
- 451 [15] Jürgen Maurer. Who has a clue to preventing the flu? unravelling supply and demand effects
452 on the take-up of influenza vaccinations. *Journal of Health Economics*, 28(3):704–717, 2009.
- 453 [16] Ylenia Brilli, Claudio Lucifora, Antonio Russo, and Marco Tonello. Vaccination take-up and
454 health: Evidence from a flu vaccination program for the elderly. *Journal of Economic Behavior*
455 *& Organization*, 179:323–341, 2020.
- 456 [17] Aziz Sheikh, Asiyah Sheikh, Zakariya Sheikh, Sangeeta Dhama, and Devi Sridhar. What’s the
457 way out? Potential exit strategies from the COVID-19 lockdown. *Journal of Global Health*,
458 10(1), 2020.
- 459 [18] Paul Fine, Ken Eames, and David L Heymann. “Herd immunity”: a rough guide. *Clinical*
460 *infectious diseases*, 52(7):911–916, 2011.

- 461 [19] Marc Lipsitch and Natalie E Dean. Understanding COVID-19 vaccine efficacy. *Science*,
462 370(6518):763–765, 2020.
- 463 [20] Thomas May and Ross D Silverman. ‘Clustering of exemptions’ as a collective action threat
464 to herd immunity. *Vaccine*, 21(11-12):1048–1051, 2003.
- 465 [21] Chris T Bauch and David JD Earn. Vaccination and the theory of games. *Proceedings of the*
466 *National Academy of Sciences*, 101(36):13391–13394, 2004.
- 467 [22] Ken TD Eames. Networks of influence and infection: parental choices and childhood disease.
468 *Journal of the Royal Society Interface*, 6(38):811–814, 2009.
- 469 [23] Thomas Rawson, Tom Brewer, Dessislava Veltcheva, Chris Huntingford, and Michael B Bon-
470 sall. How and when to end the COVID-19 lockdown: an optimization approach. *Frontiers in*
471 *Public Health*, 8:262, 2020.
- 472 [24] Thomas Rawson, Chris Huntingford, and Michael Bonsall. Temporary ‘circuit breaker’ lock-
473 downs could effectively delay a COVID-19 second wave infection peak to early spring. *Frontiers*
474 *in Public Health*, 8:899, 2020.
- 475 [25] Alex Perkins and Guido Espana. Optimal control of the COVID-19 pandemic with non-
476 pharmaceutical interventions. *medRxiv*, 2020.
- 477 [26] Gustavo Barbosa Libotte, Fran Sérgio Lobato, Antônio José da Silva Neto, and Gus-
478 tavo Mendes Platt. Determination of an Optimal Control Strategy for Vaccine Administration
479 in COVID-19 Pandemic Treatment. *arXiv preprint arXiv:2004.07397*, 2020.
- 480 [27] Analysis of death registrations not involving coronavirus (COVID-19), England and Wales: 28
481 December 2019 to 10 July 2020.
482 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/analysisofdeathregistrationsnotinvolvingcoronaviruscovid19englandandwales28december2019to1may2020/28december2019to10july2020)
483 [deaths/articles/analysisofdeathregistrationsnotinvolvingcoronaviruscovid19](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/analysisofdeathregistrationsnotinvolvingcoronaviruscovid19englandandwales28december2019to1may2020/28december2019to10july2020)
484 [englandandwales28december2019to1may2020/28december2019to10july2020](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/analysisofdeathregistrationsnotinvolvingcoronaviruscovid19englandandwales28december2019to1may2020/28december2019to10july2020). Accessed:
485 2020-11-27.

- 486 [28] Stephen A Lauer, Kyra H Grantz, Qifang Bi, Forrest K Jones, Qulu Zheng, Hannah R Mered-
487 ith, Andrew S Azman, Nicholas G Reich, and Justin Lessler. The incubation period of coro-
488 navirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and
489 application. *Annals of internal medicine*, 172(9):577–582, 2020.
- 490 [29] Conor McAloon, Áine Collins, Kevin Hunt, Ann Barber, Andrew W Byrne, Francis Butler,
491 Miriam Casey, John Griffin, Elizabeth Lane, David McEvoy, et al. Incubation period of
492 COVID-19: a rapid systematic review and meta-analysis of observational research. *BMJ open*,
493 10(8):e039652, 2020.
- 494 [30] Robert Verity, Lucy C Okell, Ilaria Dorigatti, Peter Winskill, Charles Whittaker, Natsuko Imai,
495 Gina Cuomo-Dannenburg, Hayley Thompson, Patrick GT Walker, Han Fu, et al. Estimates
496 of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious*
497 *Diseases*, 2020.
- 498 [31] Jerome R Lechien, Carlos M Chiesa-Estomba, Sammy Place, Yves Van Laethem, Pierre Caba-
499 raux, Quentin Mat, Kathy Huet, Jan Plzak, Mihaela Horoi, Stéphane Hans, et al. Clinical and
500 epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus
501 disease 2019. *Journal of internal medicine*, 2020.
- 502 [32] Jian Wu, Wei Li, Xiaowei Shi, Zhongming Chen, Bin Jiang, Jun Liu, Dawei Wang, Chengyuan
503 Liu, Yiling Meng, Leilei Cui, et al. Early antiviral treatment contributes to alleviate the
504 severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).
505 *Journal of internal medicine*, 2020.
- 506 [33] Irena Voinsky, Gabriele Baristaite, and David Gurwitz. Effects of age and sex on recovery
507 from COVID-19: Analysis of 5,769 Israeli patients. *Journal of Infection*, 2020.

508 Appendix

509 Optimal Control

510 The aim is to find an way to control infection (by minimizing disease-induced mortality) through
511 an epidemic under different transmission rates and increasing difficulty of vaccination delivery as
512 the number of vaccinated individuals increases.

513 Governing equations

514 We begin by introducing the governing equations (see main text for further details) We use an S-I-
515 R-V framework to describe the epidemiological dynamics. The dynamics for susceptible individuals
516 follow

$$\frac{dS}{dt} = -\frac{\beta S(t)I(t)}{N(t)} + \sigma R(t) - \mu S(t) - \nu(t)S(t)$$

517 The dynamics for infected individuals follow:

$$\frac{dI}{dt} = \frac{\beta S(t-\tau)I(t-\tau)}{N(t-\tau)} \exp(-\mu\tau) - (\alpha + \mu + \gamma) I(t)$$

518 The dynamics for recovered individuals follow:

$$\frac{dR}{dt} = \gamma I(t) - (\nu(t) + \mu + \sigma) R(t)$$

519 and the dynamics for the total number of vaccinated individuals are:

$$\frac{dV}{dt} = \nu(t)(R(t) + S(t)) - \mu V(t)$$

520 where β is the disease transmission rate, σ the loss of immunity, μ is the background death rate,
521 $\nu(t)$ is the vaccination rate (on both susceptible and recovered individuals), τ is the incubation win-
522 dow, α is the disease induced death rate and γ is the disease recovery rate. $N(t)=S(t)+I(t)+R(t)+V(t)$.

523

524 The objective functional is defined in terms of the rate of vaccination, the number of individuals
525 vaccinated and level of disease induced mortality such that during the epidemic of time length T

526 the 'costs' of vaccination increase. The goal is to minimize these 'costs' of vaccination and keep
 527 daily disease-induced mortality below a threshold (Z) where the control is vaccine rate ($\nu(t)$):

$$\min_{0 < \nu \leq 1} (J[\mathbf{x}, \nu]) = \min_{0 < \nu \leq 1} \left(\int_0^T \left[\frac{\nu^2(t)}{2} V(t) + \exp(\alpha I(t) - Z) \rho \right] dt \right)$$

528 where T is the length of the disease epidemic wave and Z is the critical level of daily disease induced
 529 mortality that can not be exceeded.

530

531 To solve the optimization problem, a Hamiltonian operator (H) and adjoint system (see be-
 532 low) are formed. As with all optimal control problems, the Hamiltonian operator is formed as
 533 $H = f(t, \mathbf{x}, \nu) + \lambda g(t, \mathbf{x}, \nu)$, where f represents the 'cost' function, g represents the governing equa-
 534 tions (through time t for dynamical system \mathbf{x} and control ν), and λ is a multiplier function (Kamien
 535 & Schwartz 2012). For the unstructured disease model, the Hamiltonian operator is:

536

$$\begin{aligned} H &= \frac{1}{2} \nu(t)^2 V(t) + \exp(\alpha I(t) - Z) \rho \\ &+ \lambda_1 \left(-\frac{\beta S(t) I(t)}{N(t)} + \sigma R(t) - \mu S(t) - \nu S(t) \right) \\ &+ \lambda_2 \left(\frac{\beta S(t - \tau) I(t - \tau)}{N(t - \tau)} \exp(-\mu \tau) - (\alpha + \mu + \gamma) I(t) \right) \\ &+ \lambda_3 (\gamma I(t) - (\nu + \mu + \sigma) R(t)) \\ &+ \lambda_4 (\nu(R(t) + S(t)) - \mu V(t)) \end{aligned}$$

537 Expressions for the characterization of the control are derived from minimizing the Hamiltonian
 538 operator. Each adjoint variable (λ_i) satisfies an equation found by differentiating the Hamiltonian
 539 operator with respect to the corresponding state variable, and then negating this derivative:

$$\begin{aligned} \frac{d\lambda_1}{dt} = -\frac{dH}{dS} &= \lambda_1 (\mu + \nu) - \lambda_1 \left[\frac{\beta S I}{(S + I + R + V)^2} - \frac{\beta I}{(S + I + R + V)} \right] \\ &- \lambda_2 \left[-\frac{\beta S I}{(S + I + R + V)^2} + \frac{\beta I}{(S + I + R + V)} \right] - \lambda_4 \nu \end{aligned}$$

$$\begin{aligned} \frac{d\lambda_2}{dt} = -\frac{dH}{dI} &= -exp(\alpha I - Z)\rho\alpha - \lambda_1 \left[\frac{\beta SI}{(S + I + R + V)^2} - \frac{\beta S}{(S + I + R + V)} \right] \\ &- \lambda_2 \left[-\frac{\beta SI}{(S + I + R + V)^2} + \frac{\beta S}{(S + I + R + V)} \right] + \lambda_2(\alpha + \mu + \gamma) - \lambda_3\nu \end{aligned}$$

$$\begin{aligned} \frac{d\lambda_3}{dt} = -\frac{dH}{dR} &= -\lambda_1\sigma - \lambda_1 \left(\frac{\beta SI}{(S + I + R + V)^2} \right) - \lambda_2 \left(-\frac{\beta SI}{(S + I + R + V)^2} \right) \\ &+ \lambda_3(\nu + \mu + \sigma) - \lambda_4\nu \end{aligned}$$

$$\begin{aligned} \frac{d\lambda_4}{dt} = -\frac{dH}{dV} &= -\lambda_1\sigma - \lambda_1 \left(\frac{\beta SI}{(S + I + R + V)^2} \right) - \lambda_2 \left(-\frac{\beta SI}{(S + I + R + V)^2} \right) \\ &+ \lambda_4\mu - \frac{1}{2}\nu^2 \end{aligned}$$

540 With appropriate boundary conditions, the optimal control (ν) then minimizes the Hamiltonian
541 operator such that $\frac{\partial H}{\partial \nu} = 0$ for $\nu = \nu^*$:

$$\frac{\partial H}{\partial \nu} = \nu V - \lambda_1 S - \lambda_3 R + \lambda_4(R + S).$$

542 where ν^* is :

$$\nu^* = \frac{\lambda_1 S + \lambda_3 R - \lambda_4(R + S)}{V}$$

543 The second derivative of H indicates the solution is a minimum as:

$$\frac{\partial^2 H}{\partial \nu^2} = V.$$

544 This is positive when $V > 0$, so solutions are determined as the number of vaccinated individuals
545 increases.

546 **Figures**




Figure 1: Optimal vaccination rate ν^* on disease control (from the unstructured S-I-R-V model) under a fixed critical threshold (Z) that instantaneous disease-induced deaths should not exceed. (A) The effects of reducing transmission (β) on disease dynamics for, in red, no reduction in transmission ($\beta = 0.8$) with progressive reductions (20%, 40%, 60% and 80%) in transmission shown in black ($Z = 100$). (B) Optimal vaccination rate for different transmission rates for different fixed critical threshold (Z) (blue points $Z = 10$; red points $Z = 100$). Optimal vaccination rate with low transmission (severe lockdown) reduces the potential for epidemic disease epidemics and minimize number of deaths. (Other parameters: $\beta = 0.8$, $\alpha = 0.01$, $\gamma = 0.1$, $\mu = 0.001$, $\rho = 1.0$).




Figure 2: Combined effects of vaccination and lockdown durations (rainbow colours blue/purple - short (15 days) through to red - long (95 days)) for different lockdown severities (where transmission is reduced by (a) 20%, (b) 40%, (c) 60% and (d) 80%) on cumulative deaths. For vaccination to be at all effective in reducing cumulative mortality (say 50K over 150 days) in the range of coverage anticipated (Figure B 0.006 - 0.0152) then lockdown severity needs to reduce transmission by at least 60% or lockdown durations need to be unduly long.




Figure 3: Optimal combination of vaccination rates (covering an expected vaccination rate range of 0.006 - 0.0152) and length of lockdowns to (under different severity to keep cumulative deaths below (a) 50K (b) 60K (c) 70K or (d) 80K for different lockdown severity (purple - 80% reduction in β , blue - 60% reduction in β , green - 40% reduction in β , red - 20% reduction in β). From (a) – 50K mortality threshold, for a weakly efficacious vaccination rate (0.005), depending on the severity of lockdown, lockdown durations could be 30 days (for 80% reduction in beta) or 70 days (for 60% reduction in beta). At this level of vaccination (0.005) and for a lockdown where β is only reduced by 20% or 40% it is not feasible to keep cumulative mortality below the 50K threshold.




Figure 4: Combinations of vaccination across different groups: (a) all groups vaccinated (b) only key worker group vaccinated (c) only vulnerable group vaccinated (d) only non-vulnerable group vaccinated, lockdown duration (in days) and lockdown severities (in terms of reducing transmission - (purple - 80% reduction in β , blue - 60% reduction in β , green - 40% reduction in β , red - 20% reduction in β)) on keeping cumulative mortality less than 80K. Vaccination across the non-vulnerable group provides greater opportunities to keep mortality below critical threshold with lockdowns of short duration and/or less restrictive.




Figure 5: Vaccine sequence to minimize cumulative mortality (below 80K) for varying duration and severity of lockdown and vaccination rate. Sequence is to deliver vaccine to first group for 30 days, first and second group from 31-60 days and all groups after 60 days. Only moderately severe (reducing transmission by 60%) or severe (reducing transmission by 80%) achieve optimal control of mortality. Including non-vulnerable group (NV) in first or second phase of vaccination achieves better control and can reduce the severity and duration of lockdowns. If front-line workers (FR) are first in line for vaccination then the optimal sequence is shown in figure B . If vulnerable group (V) is first in line then to achieve optimal control of mortality requires vaccination of non-vulnerable group before key worker group (figure D). [(purple line - 80% reduction in β , blue line - 60% reduction in β , green line - 40% reduction in β)]




Figure 6: Effects of declining vaccine demand uptake and length of lockdowns (in days) on cumulative virus-induced mortality (dashed line shows 50K threshold) for different lockdown severities (as reductions in virus transmission during lockdown). Fixed (inelastic) vaccine demand always leads to the lowest levels of cumulative mortality (red line). For declining (elastic) vaccine demand, rapidly (exponential) declining vaccine uptake (blue line) leads to the largest difference from fixed vaccine (compared to linear ((orange line) or polynomial declines (green line)). The effects of elastic vaccine demand on cumulative mortality can be offset by increasing length (days) and severity (reduction in virus transmission) of lockdowns.